About TearLab (TSE:TLB)
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.
Industry, Sector and Symbol:
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Sector: Healthcare
- Symbol: TSE:TLB
- CUSIP: N/A
- Web: www.tearlab.com
- Outstanding Shares: 5,742,000
Frequently Asked Questions for TearLab (TSE:TLB)
What is TearLab's stock symbol?
TearLab trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TLB."
When will TearLab make its next earnings announcement?
Who are some of TearLab's key competitors?
Some companies that are related to TearLab include Metabolix (YTEN), Ixico Plc (IXI), Avinger (AVGR), Great Basin Scientific (GBSN), Baxano Surgical (BAXSQ), Savient Pharmaceuticals (SVNTQ), NephroGenex (NRXGQ), Air Methods Corp (AIRM), Alexza Pharmaceuticals (ALXA), Allos Therapeutics (ALTH), Amgen Rockville (MITI), Amylin Pharmaceuticals LLC (AMLN), Ardea Biosciences (RDEA), Ariad Pharmaceuticals (ARIA), ArthroCare Corporation (ARTC), Avanir Pharmaceuticals (AVNR), Baxalta (BXLT) and Bayer Essure (CPTS).
Who are TearLab's key executives?
TearLab's management team includes the folowing people:
- Elias Vamvakas, Chairman of the Board (Age 58)
- Joseph S. Jensen, President, Chief Executive Officer, Chief Operating Officer, Director (Age 45)
- Wes Brazell, Chief Financial Officer (Age 51)
- Raymond Kong, Vice President - Sales
- Anthony E. Altig, Independent Director (Age 61)
- Thomas N. Davidson Jr., Independent Director (Age 57)
- Adrienne L. Graves Ph.D., Independent Director (Age 63)
- Paul M. Karpecki, Independent Director (Age 49)
- Richard L. Lindstrom M.D., Independent Director (Age 69)
How do I buy TearLab stock?
Shares of TearLab and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is TearLab's stock price today?
One share of TearLab stock can currently be purchased for approximately C$0.97.
How big of a company is TearLab?
TearLab has a market capitalization of C$5.68 million.
How can I contact TearLab?
TearLab's mailing address is 9980 Huennekens St Ste 100, SAN DIEGO, CA 92121-2968, United States. The company can be reached via phone at +1-858-7941400.
MarketBeat Community Rating for TearLab (TSE TLB)MarketBeat's community ratings are surveys of what our community members think about TearLab and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for TearLab (TSE:TLB) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for TearLab (TSE:TLB)
Analysts' Ratings History for TearLab (TSE:TLB)
(Data available from 11/20/2015 forward)
|8/16/2017||HC Wainwright||Reiterated Rating||Buy|
Earnings History for TearLab (TSE:TLB)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for TearLab (TSE:TLB)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for TearLab (TSE:TLB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for TearLab (TSE TLB)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for TearLab (TSE TLB)
Financials are not available for this stock.
TearLab (TSE TLB) Chart for Monday, November, 20, 2017